FDA
-
-
-
-
-
-
-
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
-
-
-
-
-
-
-
Purple Biotech (PPBT) Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
-
-
-
-
-
-
-
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
-
-
-
-
-
-
-
Purple Biotech Debuts Scientific Advisory Board
-
-
-
-
-
-
-
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
-
-
-
-
-
-
-
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
-
-
-
-
-
-
-
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

